Saturday 17 October 2026
Export DMTKQ’s income statement to Excel — free account
DermTech, Inc.
DMTKQ Healthcare Diagnostics & Research
DermTech, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.3 million, up 5.36% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow DMTKQ
DermTech, Inc. (DMTKQ) P/E ratio
DermTech, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (August 2025) to 247× (October 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 18 more quarters | Free account |
Against its own ten years
Low 0.0×
High 247×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DMTKQ DermTech, Inc. | n/m |
| NOTVQ Inotiv, Inc. compare | n/m |
| TTOO T2 Biosystems, Inc. compare | n/m |
| XWEL XWELL, Inc. compare | n/m |
| ISPC iSpecimen Inc. compare | n/m |
| NDRA ENDRA Life Sciences Inc. compare | n/m |
| BIAF bioAffinity Technologies, Inc. compare | n/m |
| AWHL Aspira Women's Health Inc. compare | n/m |
| ADVB Advanced Biomed Inc. compare | 0.8× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)